Utilidad de la alfafetoproteína sérica materna como parámetro de riesgo del embarazo

Article information

Resumen

Objetivo

Demostrar que las embarazadas con valores elevados, sin justificación aparente, de alfafetoproteína sérica tienen un riesgo mayor de resultados perinatales adversos

Sujetos y métodos

Se estudiaron 43.424 gestantes desde el segundo trimestre del embarazo hasta el parto. Se calculó el riesgo relativo entre los valores de alfafetoproteína en suero materno (AFPSM) y los resultados perinatales siguientes: partos pretérminos, muertes fetales anterior y posterior a la semana 28 de gestación, y recién nacidos con bajo peso

Resultados

Se estudió la influencia de las concentraciones de AFPSM sobre 4 resultados perinatales adversos, observándose en todos ellos una diferencia significativa entre el grupo de gestantes considerado control (AFPSM < 2,5 múltiplos de la mediana [MDM]) y el grupo de riesgo (AFPSM > 2,5 MDM). Se observó un mayor riesgo relativo en las gestantes con muerte fetal anterior a la semana 28 de gestación

Conclusiones

Se ha comprobado que existe una relación entre los valores elevados de AFPSM y el riesgo de un resultado perinatal adverso. Sin embargo, la AFPSM no se puede considerar un marcador de cribado adecuado, por su baja sensibilidad, para seleccionar gestantes con un riesgo elevado de un resultado adverso

Palabras clave:

Alfafetoproteínas

Bajo peso

Parto pretérmino

Muerte fetal

Abstract

Objective

To show that pregnant women with an unexplained maternal serum alphafetoprotein (MSAFP) elevation are at increased risk for adverse perinatal outcomes

Patients and methods

43.424 pregnant women were studied prospectively from the early second trimester until delivery. A risk factor for preterm delivery, fetal death, before and after 28 weeks of gestation, and low birth weight infants was calculated from the clinical history and MSAFP concentrations

Results

In all the groups increasing levels of MSAFP are significatively associated with adverse perinatal outcomes, showing a significative difference with regard to the control group of pregnancies (MSAFP < 2,5 multiples of the median [MDM]). The highest relative risk was observed from pregnancies with fetal death before 28 weeks of gestation

Conclusions

Pregnant women with unexplained elevations of MSAFP are at increased risk for adverse perinatal outcomes. However, the MSAFP, because of its low sensitivity, can not be considered as a screening tool to select this kind of pregnancies

Keywords:

Alpha-fetoprotein

Low birth-weight

Preterm delivery

Fetal death

Full text is only aviable in PDF

Bibliografía

[1.]

M. Sepala, E. Ruoslahti.

Alphafetoprotein in maternal serum: a new marker for detection of fetal distress and intrauterine death.

Am J Obstet Gynecol, 115 (1973), pp. 48-52

Medline

[2.]

S.N. Dyer, T.K. Burton, L.H. Nelson.

Elevated maternal serum alphafetoprotein and oligohydramnios: poor prognosis for pregnancy outcome.

Am J Obstet Gynecol, 157 (1987), pp. 336-339

Medline

[3.]

S. Pintado, R. Fernández-Collar, R. Villa, M. Cándenas, F. García-Sáez, F.V. Álvarez.

Alfafetoproteína sérica materna elevada y oligoamnios: resultados obstétricos y pronóstico fetal.

Prog Obstet Ginecol, 36 (1993), pp. 59-64

[4.]

J.A. Clayton-Hopkins, P.N. Olsen, A.P. Blake.

Maternal serum alpha-fetoprotein levels in the pregnancy complicated by hypertension.

Prenat Diagn, 2 (1982), pp. 47-54

[5.]

R. Raty, P. Koskinen, A. Alanen, K. Irjala, I. Matinlauri, U. Ekblad.

Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A. AFP and free beta-hCG levels.

Prenat Diag, 19 (1999), pp. 122-127

[6.]

D.K. Waller, L.S. Lustig, G.C. Cunningham, M.S. Golbus, E.B. Hook.

Second trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death.

N Engl J Med, 325 (1991), pp. 6-10

http://dx.doi.org/10.1056/NEJM199107043250102 | Medline

[7.]

R.O. Davis, R.L. Goldenberg, L. Boots, H.J. Hoffman, R. Copper, G.R. Cutter, et al.

Elevated levels of midtrimester maternal serum alfa-fetoprotein are associated with preterm delivery but not with fetal growth retardation.

Am J Obstet Gynecol, 167 (1992), pp. 596-601

Medline

[8.]

M. McLean, A. Bisits, J. Davies, W. Walters, A. Hackshaw, K. De Voss, et al.

Predicting risk of pretern delivery by second trimester measurement of maternal plasma corticotropin-releasing hormone and alpha-fetoprotein concentrations.

Am J Obstet Gynecol, 181 (1999), pp. 207-215

Medline

[9.]

J.E. Haddow, G.E. Palomaki, G.J. Knight.

Can low birth weight after elevated maternal serum alphafetoprotein be explained by maternal weight?.

Obstet Gynecol, 70 (1987), pp. 26-28

Medline

[10.]

J.N. Macri, R.R. Weiss, B. Libster, M.A. Cagan.

Maternal serum alphafetoprotein and low birth-weight.

Lancet, 311 (1978), pp. 660

[11.]

L.H. Nelson, J. Bensen, B.K. Burton.

Outcomes in patients with unusually high maternal serum alphafetoprotein levels.

Am J Obstet Gynecol, 57 (1987), pp. 572-576

[12.]

W. Cusick, J.F. Rodis, A.M. Vintzileos, S.M. Albini, M. McMahon, W.A. Campbell.

Predicting pregnancy outcome from the degree of maternal serum alphafetoprotein elevation.

J Reprod Med, 41 (1996), pp. 327-332

Medline

[13.]

C.G. Brumfield, G.A. Cloud, S.C. Finley, P. Cosper, R.O. Davis, J.F. Huddleston.

Amniotic fluid alphafetoprotein levels and pregnancy outcome.

Am J Obstet Gynecol, 157 (1987), pp. 822-825

Medline

[14.]

E. Verspyck, S. Degre, M.F. Hellot, G. Descargues, C. Philippe, G. Labadie, et al.

Amniotic fluid alpha-fetoprotein is not a useful biological marker of pregnancy outcome.

Prenat Diag, 19 (1999), pp. 1031-1034

[15.]

J. Evans, I.M. Stokes.

Outcome of pregnancies associated with raised serum and normal amniotic fluid alphafetoprotein concentrations.

Br Med J, 288 (1984), pp. 1494

[16.]

A. Drugan, J.E. O'Brien, E. Dvorin, E.L. Krivchenia, M.P. Johnson, R.J. Sokol, et al.

Multiple marker screening in multifetal gestations: failure to predict adverse pregnancy outcomes.

Fetal Diag Ther, 11 (1996), pp. 16-19

[17.]

J.R. Beekhuis, J.M.M.M. Van Lith, B.T.H.M. De Wolf, A. Mantingh.

Increased maternal serum alphafetoprotein and human chorionic gonadotrpin in compromised pregnancies other than for neural tube defects or Down syndrome.

Prenat Diag, 12 (1992), pp. 643-647

[18.]

A. Kelemen, B. Pejtsik, J. Bodis, G. Rappay.

Relationship between maternal serum levels of alphafetoprotein and human chorionic gonadotropin in the early second trimester.

Prenat Diag, 17 (1997), pp. 883-890

[19.]

F. Muller, P. Aegerter, A. Boue.

Prospective maternal serum human chorionic gonadotropin screening for the risk of fetal chromosome anomalies and of subsequent fetal and neonatal deaths.

Prenat Diag, 13 (1993), pp. 29-43

[20.]

K.D. Wenstrom, J. Owen, L.R. Boots, M.B. DuBard.

Elevated second- trimester human chorionic gonadotropin levels in association with poor pregnancy outcome.

Am J Obstet Gynecol, 171 (1994), pp. 1038-1041

Medline

[21.]

G. Blundell, J.P. Ashby, C. Martin, C.H. Shearing, B. Langdale-Brown, J. Keeling, et al.

Clinical follow-up of high mid-trimester maternal serum intact human chorionic gonadotropin concentrations in singleton pregnancies.

Prenat Diag, 19 (1999), pp. 219-223

[22.]

R. Zanini, M. Tarantini, V. Cerri, C. Jacobello, S. Lancetti, S. Scalchi, et al.

“Dual positivity” for neural tube defects and Down syndrome at maternal screening: gestational outcome.

Fetal Diag Ther, 13 (1998), pp. 106-110

[23.]

P.A. Benn.

Down syndrome and open neural tube defects screen positive pregnancies: premature delivery and premature placental karyotyping.

Prenat Diag, 17 (1997), pp. 282-284

[24.]

L.P. Morssink, L.H. Kornman, J.R. Beekhuis, B.T.H.M. De Wolf, A. Martingh.

Abnormal levels of maternal serum human chorionic gonadotropin and alphafetoprotein in the second trimester: relatio to fetal weight and preterm delivery.

Prenat Diag, 15 (1995), pp. 1041-1046

[25.]

W. Furhman, H. Weitzel.

Maternal serum alphafetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.

Hum Genet, 69 (1985), pp. 47-61

Medline

[26.]

M. Cándenas, R. Villa, R. Fernández Collar, M.J. Moína, S. Pintado, F. García-Sáez, et al.

Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a program with more than 30000 screened pregnancies.

Act Obstet Gynecol Scand, 74 (1995), pp. 266-269

[27.]

J.M. Larson, D.H. Pretorius, N.E. Budorick, A.L. Scioscia.

Value of maternal serum alphafetoprotein levels of 5,0 MOM or greater and prenatal sonography in predicting fetal outcome.

Radiology, 189 (1993), pp. 77-81

http://dx.doi.org/10.1148/radiology.189.1.7690492 | Medline

[28.]

H.S. Cuckle, N.J. Wald, P.M. Cuckle.

Prenatal screening and diagnosis of neural tube defects in England and Wales in 1985.

Prenat Diag, 9 (1989), pp. 393-400

[29.]

L.P. Morssink, M.P. Heringa, J.R. Beekhuis, B.T.H.M. De Wolf, A. Mantingh.

The HELLP syndrome is associated with unexplained elevation of MSAFP and MShCG in the second trimester.

Prenat Diag, 17 (1997), pp. 601-606

[30.]

T.D. Shipp, L. Wilkins-Haug.

The association of early-onset fetal growth restriction, elevated maternal serum alphafetoprotein and the development of severe pre-eclampsia.

Prenat Diag, 17 (1997), pp. 305-309

[31.]

D.K. Waller, J.L. Mills, J.L. Simpson, G.C. Cunningham, M.R. Conley, M.R. Lassman, et al.

Are obese women at higher risk for producing malformed offspring?.

Am J Obstet Gynecol, 170 (1994), pp. 541-548

Medline

[32.]

D.J.H. Brock, L. Barron, G.M. Raab.

The potential of midtrimester maternal plasma alphafetoprotein measurement in predicting infants of low birth weight.

Br J Obstet Gynecol, 87 (1980), pp. 582-585

[33.]

B.K. Burton, R.G. Dillard.

Outcome in infants born to mothers with unexplained elevations of maternal serum alphafetoprotein.

Pediatrics, 77 (1986 b), pp. 582-586

Medline

[34.]

C.M. Salafia, L. Silberman, N.E. Herrera, M.J. Mahoney.

Placental pathology at term associated with elevated midtrimester maternal serum alphafetoprotein concentration.

Am J Obstet Gynecol, 158 (1988), pp. 1064-1066

Medline

[35.]

T. Chard, A. Rice, M.J. Kutau, V. Hird, J.G. Grudzinskas, A.M. Nysenbaum.

Midtrimester levels of alphafetoprotein in the screening of low birth-weight.

Br J Obstet Gynecol, 93 (1986), pp. 36-38

[36.]

J.E. Maher, R.O. Davis, R.L. Goldenberg, L.R. Boots, M.B. Dubard.

Unexplained elevation in maternal serum alphafetoprotein and subsequent fetal loss.

Obstet Gynecol, 83 (1994), pp. 138-141

Medline

El trabajo fue realizado en el Laboratorio de Bioquímica del Hospital San Agustín de Avilés. El presente trabajo ha sido realizado en parte con soporte económico de Roche Diagnostics, España

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter